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Abstract 
The cytosine arabinoside cytarabine is an effective marine-derived antineoplastic 
agent for the treatment of acute myelogrnous and lymphocytic leukemias. As this 
nucleoside antimetabolite is an S-phase-specific drug, prolonged exposure of cells to 
toxic concentrations is critical to achieve maximum biological effect. The activity of 
cytarabine is nevertheless decreased by its rapid deamination to the biologically 
inactive metabolite uracil arabinoside. This rapid degradation process is the reason for 
the ongoing search for efficient formulations and derivatives of cytarabine that cannot 
be deaminated and exhibited better pharmacokinetic parameters. In the present 
study, pegylated liposomes were modified for intended prolonged delivery of 
cytarabine and tested for improved cytotoxic and cytostatic effect in different human 
cancer lines. 
 
 
 
 
 
 
 
  
